The RSI Oscillator for DFTX moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 28 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 60 cases where DFTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on DFTX as a result. In 83 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for DFTX just turned positive on October 21, 2026. Looking at past instances where DFTX's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Following a +2.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where DFTX advanced for three days, in 239 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
DFTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DFTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for DFTX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.265) is normal, around the industry mean (2.973). P/E Ratio (-10.496) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. DFTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DFTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
On October 20, 2026, the Stochastic Oscillator for PRAX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 49 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 89%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PRAX's RSI Indicator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for PRAX just turned positive on October 20, 2026. Looking at past instances where PRAX's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.
Following a +9.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in 258 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PRAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 50-day moving average for PRAX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for PRAX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.391) is normal, around the industry mean (2.973). P/E Ratio (-19.978) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DFTX | PRAX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 63 | 61 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 20 Undervalued | 17 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 37 | 63 | |
P/E GROWTH RATING 1..100 | 24 | 25 | |
SEASONALITY SCORE 1..100 | 42 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRAX's Valuation (17) in the null industry is in the same range as DFTX (20). This means that PRAX’s stock grew similarly to DFTX’s over the last 12 months.
PRAX's Profit vs Risk Rating (100) in the null industry is in the same range as DFTX (100). This means that PRAX’s stock grew similarly to DFTX’s over the last 12 months.
PRAX's SMR Rating (97) in the null industry is in the same range as DFTX (98). This means that PRAX’s stock grew similarly to DFTX’s over the last 12 months.
DFTX's Price Growth Rating (37) in the null industry is in the same range as PRAX (63). This means that DFTX’s stock grew similarly to PRAX’s over the last 12 months.
DFTX's P/E Growth Rating (24) in the null industry is in the same range as PRAX (25). This means that DFTX’s stock grew similarly to PRAX’s over the last 12 months.
| DFTX | PRAX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 86% | N/A |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 83% |
| Advances ODDS (%) | 1 day ago 86% | 3 days ago 85% |
| Declines ODDS (%) | 9 days ago 80% | 9 days ago 83% |
| BollingerBands ODDS (%) | 1 day ago 79% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 83% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DFTX’s FA Score shows that 2 FA rating(s) are green while PRAX’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DFTX’s TA Score shows that 6 TA indicator(s) are bullish while PRAX’s TA Score has 5 bullish TA indicator(s).
DFTX (@Biotechnology) experienced а +3.65% price change this week, while PRAX (@Biotechnology) price change was +4.30% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
DFTX is expected to report earnings on Nov 05, 2026.
PRAX is expected to report earnings on Nov 04, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, DFTX has been loosely correlated with IDYA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DFTX jumps, then IDYA could also see price increases.
| Ticker / NAME | Correlation To DFTX | 1D Price Change % | ||
|---|---|---|---|---|
| DFTX | 100% | +1.44% | ||
| IDYA - DFTX | 39% Loosely correlated | +1.83% | ||
| CGEM - DFTX | 38% Loosely correlated | +0.20% | ||
| RLAY - DFTX | 38% Loosely correlated | -0.38% | ||
| PRAX - DFTX | 38% Loosely correlated | +0.96% | ||
| KYMR - DFTX | 38% Loosely correlated | -1.58% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ABCS | 35.53 | 0.55 | +1.57% |
| Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS) | |||
| TYLD | 25.38 | N/A | N/A |
| Cambria Tactical Yield ETF (TYLD) | |||
| LOWV | 85.27 | -0.31 | -0.36% |
| AB US Low Volatility Equity ETF (LOWV) | |||
| CGUS | 44.37 | -0.67 | -1.49% |
| Capital Group Core Equity ETF (CGUS) | |||
| GTOP | 47.81 | -1.76 | -3.56% |
| Goldman Sachs Technology Opportunities ETF (GTOP) | |||